These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 16952649

  • 1. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
    Divrik RT, Akdoğan B, Ozen H, Zorlu F.
    J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
    [Abstract] [Full Text] [Related]

  • 2. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
    Ondrus D, Ondrusova M, Hornak M, Matoska J.
    Neoplasma; 2007 Oct; 54(5):437-42. PubMed ID: 17688374
    [Abstract] [Full Text] [Related]

  • 3. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH, Schefer H, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE.
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [Abstract] [Full Text] [Related]

  • 4. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN.
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance.
    Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JF, Moore M, Jewett MA.
    J Urol; 1997 May; 157(5):1705-9; discussion 1709-10. PubMed ID: 9112510
    [Abstract] [Full Text] [Related]

  • 7. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D, Borner M, Sonntag RW, Fey MF, Studer UE.
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
    Ondrus D, Goncalves F, Kausitz J, Mat'oska J, Belan V.
    Neoplasma; 1996 Apr; 43(3):195-7. PubMed ID: 8841507
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
    Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW.
    Cancer; 1998 Sep 01; 83(5):1002-11. PubMed ID: 9731905
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
    Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A, Barnadas A, Dorca J, Gumà J, Olmos D, Bastús R, Carles J, Almenar D, Sánchez M, Paz-Ares L, Satrústegui JJ, Mellado B, Balil A, López-Brea M, Sánchez A, Second Spanish Germ Cell Cancer Cooperative Group.
    J Clin Oncol; 2005 Dec 01; 23(34):8717-23. PubMed ID: 16260698
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
    Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL.
    J Urol; 2007 Jan 01; 177(1):131-8. PubMed ID: 17162023
    [Abstract] [Full Text] [Related]

  • 17. Prognosis of patients after retroperitoneal lymphadenectomy for clinical stage I nonseminomatous germ cell tumour of the testis.
    Hornák M, Zvara V, Ondrus D, Bárdos A.
    Czech Med; 1987 Jan 01; 10(2):109-16. PubMed ID: 2820669
    [Abstract] [Full Text] [Related]

  • 18. [Management of stage I testicular nonseminomatous germ cell tumors with an embryonic carcinomatous component. 18 cases].
    Drianno N, Robert M, Legouffe E, Guiter J, Navratil H.
    Prog Urol; 1997 Sep 01; 7(4):622-7. PubMed ID: 9410322
    [Abstract] [Full Text] [Related]

  • 19. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.
    J Clin Oncol; 2005 Apr 20; 23(12):2781-8. PubMed ID: 15837993
    [Abstract] [Full Text] [Related]

  • 20. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
    Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, Warde PR, Gospodarowicz MK, Alison RE, Liu J, Ma C, Pond GR, Jewett MA.
    Eur Urol; 2011 Apr 20; 59(4):556-62. PubMed ID: 21190791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.